1 September 2011
Reckitt Benckiser Group plc
DIRECTORATE CHANGE
Further to the announcement made on 14 April 2011, Reckitt Benckiser Group plc
(RB) today confirms the retirement of Bart Becht and the appointment of Rakesh
Kapoor as CEO and executive director with immediate effect.
Mr Becht will remain a part-time adviser to Mr Kapoor and the RB Board until
September 2012 to support the leadership transition.
The following information is given in accordance with Listing Rule 9.6.13:
* Rakesh Kapoor has not held a directorship in any publicly quoted company in
the past five years.
* There are no further disclosures to be made pursuant to Listing Rule
9.6.13.
For further information:
Elizabeth Richardson
Company Secretary
Telephone +44 (0) 1753 217 800
Notes for Editors:
Reckitt Benckiser (RB) is a world leader in household, health and personal
care.
It is a FTSE top 25 company and since 2000 net revenues have doubled and the
market cap has quadrupled. Today it is the global No 1 or No 2 in the majority
of its fast-growing categories, driven by an exceptional rate of innovation -
typically about 35% of net revenue comes from innovations launched in the prior
3 years. It has a strong portfolio led by 19 global powerbrands which are:
Finish, Lysol, Dettol, Vanish, Woolite, Durex, Calgon, Airwick, Harpic, Bang,
Mortein, Veet, Nurofen, Clearasil, Strepsils Gaviscon, Mucinex, Scholl and
French's, and they account for 69% of net revenue.
RB people are at the heart of the company's success. They have an intense drive
for progress and action and a desire to outperform wherever they focus,
including in CSR where the company has the most ambitious corporate
responsibility programme in the industry through its Carbon 20 initiative.
Headquarters in the United Kingdom, the company employs about 27,000 people
worldwide, with operations in over 60 countries and sales in almost 200
countries.
For more information visit RB.COM
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.